INKON Life Technology Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Wen Peng

Algemeen directeur

CN¥1.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

CEO

Wen Peng (56 yo)

3.3yrs

Tenure

CN¥1,778,900

Compensatie

Mr. Wen Peng has been General Manager of INKON Life Technology Co., Ltd. since August 25, 2021 and has been its Non-Independent Director since September 14, 2020. Mr. Peng served as the Deputy General Mana...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wen Peng	GM & Director	3.3yrs	CN¥1.78m	geen gegevens
Lan Jiang	Financial Director	1.2yrs	CN¥202.10k	geen gegevens
Zelin Liu	Board Secretary	2yrs	CN¥506.20k	geen gegevens
Hongbo Li	Deputy General Manager	4.6yrs	CN¥1.05m	geen gegevens
Jinchen Xie	Accounting Supervisor	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300143 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wen Peng	GM & Director	4.2yrs	CN¥1.78m	geen gegevens
Lixia Tan	Chairman	5.5yrs	geen gegevens	geen gegevens
Xudong Shen	Non-Independent Director	5.5yrs	CN¥1.26m	geen gegevens
Mianshun Pan	Non-Independent Director	4.2yrs	CN¥457.60k	geen gegevens
Wenwen Gong	Chairman of the Supervisory Board	4.2yrs	geen gegevens	geen gegevens
Xudong Wang	Employee Representative Supervisor	5yrs	geen gegevens	geen gegevens
Xiaoman Chen	Independent Director	1.2yrs	CN¥30.00k	geen gegevens
Yuan Du	Independent Director	1.2yrs	CN¥30.00k	geen gegevens
Feng Jiang	Independent Director	1.2yrs	CN¥30.00k	geen gegevens

4.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300143 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

INKON Life Technology Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

High number of new directors

High number of new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.039 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 32%

INKON Life Technology Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Now 23% undervalued

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.057 in 2Q 2023)

INKON Life Technology Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥1.01 loss in FY 2022)

INKON Life Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

INKON Life Technology Co., Ltd. (SZSE:300143) announces an Equity Buyback for CNY 80 million worth of its shares.

INKON Life Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.013 in 3Q 2022)

Now 21% undervalued after recent price drop

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

INKON Life Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.036 in 2Q 2022)

Full year 2022 earnings released: CN¥1.01 loss per share (vs CN¥0.57 loss in FY 2021)

High number of new directors

High number of new directors

Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. (SZSE:300143) agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million.

Third quarter 2022 earnings released: EPS: CN¥0.013 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.019 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.038 (vs CN¥0.018 in 1Q 2021)

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.026 in 3Q 2020)

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million.

Second quarter 2021 earnings released: EPS CN¥0.019 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.021 loss in 1Q 2020)

INKON Life Technology Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥18.00

New 90-day low: CN¥20.30

New 90-day low: CN¥21.84

New 90-day low: CN¥22.19

Third quarter earnings released

First half earnings released

New 90-day high - CN¥25.25

INKON Life Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

INKON Life Technology Co., Ltd. announced that it has received CNY 732.939997 million in funding from Qingdao Yingkang Medical Investment Co., Ltd.

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd